Trial Profile
Case-control Study to Evaluate the Vaccine Effectiveness of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) Against Community-acquired Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 October 2006, in Belgium.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Gastroenteritis; Rotavirus infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 29 Oct 2010 Planned number of patients changed from 603 to 643, according to ClinicalTrials.gov.
- 23 Aug 2010 New trial record